Limits...
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse.

Ahmed F, Zafar HW, Buture A, Khalil M - Springerplus (2015)

Bottom Line: Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications.The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting.OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ UK.

ABSTRACT
Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications. Withdrawal of analgesics is often advised before commencing preventive treatments. However, some headache experts recommend preventive treatments alongside analgesic withdrawal. 434 patients with chronic migraine attending the Hull Headache Clinic who received OnabotulinumtoxinA as preventive treatment were stratified to those with or without analgesic overuse. Data was collected through a dedicated headache diary and analysed for headache and migraine days reduction and for an increment in headache-free days in the month post treatment. The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting. OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

No MeSH data available.


Related in: MedlinePlus

50 % response on three key outcome parameters
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4628076&req=5

Fig5: 50 % response on three key outcome parameters

Mentions: Table 5 shows a comparison of 50 and 75 % responder rate between the two groups. The results show no difference in reduction of headache and migraine days between the two groups. However, patients with medication overuse had more crystal clear days post-treatment than those without medication overuse. This may be attributed to fewer crystal clear days before treatment in those with medication overuse. Figures 5 and 6 graphically demonstrate the 50 and 75 % response rate in the two groups.Table 5


Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse.

Ahmed F, Zafar HW, Buture A, Khalil M - Springerplus (2015)

50 % response on three key outcome parameters
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4628076&req=5

Fig5: 50 % response on three key outcome parameters
Mentions: Table 5 shows a comparison of 50 and 75 % responder rate between the two groups. The results show no difference in reduction of headache and migraine days between the two groups. However, patients with medication overuse had more crystal clear days post-treatment than those without medication overuse. This may be attributed to fewer crystal clear days before treatment in those with medication overuse. Figures 5 and 6 graphically demonstrate the 50 and 75 % response rate in the two groups.Table 5

Bottom Line: Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications.The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting.OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ UK.

ABSTRACT
Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications. Withdrawal of analgesics is often advised before commencing preventive treatments. However, some headache experts recommend preventive treatments alongside analgesic withdrawal. 434 patients with chronic migraine attending the Hull Headache Clinic who received OnabotulinumtoxinA as preventive treatment were stratified to those with or without analgesic overuse. Data was collected through a dedicated headache diary and analysed for headache and migraine days reduction and for an increment in headache-free days in the month post treatment. The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting. OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

No MeSH data available.


Related in: MedlinePlus